Andrew Graf
Internal Medicine · Plymouth Meeting, PANPI 1316108269
Payments from drug & device makers
Across 392 payments — averaging $433.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$112K
- Otsuka America Pharmaceutical, Inc.$41K
- Johnson & Johnson$6K
- Urovant Sciences Inc$4K
- Sumitomo Pharma America, Inc.$3K
- Sunovion Pharmaceuticals Inc.$709
- plus $3K from 28 others
What the payments were for
- Consulting fees$4,2763%
- Speaking & faculty fees$148,26887%
- Travel & lodging$7,8385%
- Food & beverage$9,6176%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 137 | $112,227 |
| Otsuka America Pharmaceutical, Inc. | 56 | $41,268 |
| Johnson & Johnson | 16 | $6,253 |
| Urovant Sciences Inc | 5 | $3,518 |
| Sumitomo Pharma America, Inc. | 9 | $2,963 |
| Sunovion Pharmaceuticals Inc. | 45 | $709 |
| Acadia Pharmaceuticals Inc | 17 | $467 |
| Novartis | 17 | $329 |
| AstraZeneca(2 entities) | 6 | $311 |
| Teva Pharmaceuticals USA, Inc. | 11 | $282 |
| UCB, Inc. | 12 | $258 |
| Pfizer | 13 | $223 |
| Astellas Pharma US Inc | 8 | $214 |
| E.r. Squibb & Sons, L.L.C. | 5 | $174 |
| Bayer | 1 | $107 |
| Abbott | 3 | $101 |
| Sun Pharmaceutical Industries Inc. | 4 | $98 |
| Biogen | 1 | $80 |
| AbbVie(2 entities) | 4 | $74 |
| Lilly USA, LLC | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $38 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Boston Scientific | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| MDD US Operations, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Amphastar Pharmaceuticals, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $12 |
| Amgen | 1 | $11 |
| EDW Pharma, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$170,000 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 5,347 | $1,406,964 |
| XareltoRivaroxaban | 1,202 | $323,015 |
| NuplazidPimavanserin Tartrate | 82 | $248,669 |
| IngrezzaValbenazine Tosylate | 38 | $212,352 |
| TrulicityDulaglutide | 252 | $184,584 |
| XifaxanRifaximin | 149 | $167,030 |
| Tetrabenazine | 39 | $148,136 |
| JardianceEmpagliflozin | 612 | $144,403 |
| Invega SustennaPaliperidone Palmitate | 41 | $136,742 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $131,508 |
| OzempicSemaglutide | 120 | $124,771 |
| Atorvastatin Calcium | 8,372 | $111,027 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 195 | $102,079 |
| SantylCollagenase Clostridium Hist. | 125 | $96,349 |
| Humira(Cf) PenAdalimumab | 13 | $96,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $1,406,9645,347 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Risperdal Consta | $6,253 | $507,5571,295 claims |
| Acadia Pharmaceuticals IncNuplazid | $467 | $248,66982 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15 | $212,878935 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $15 | $212,35238 claims |
| Lilly USA, LLCTrulicity | $55 | $184,584252 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $14 | $167,030149 claims |
| Smith+NephewSantyl | $12 | $96,349125 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $112,227 | $88,694148 claims |
| AmgenOtezla | $11 | $84,05335 claims |
| NovartisEntresto | $329 | $77,699304 claims |
| AstraZenecaFarxiga | $311 | $69,279260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Plymouth Meeting
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.